Net Cash Provided by (Used in) Financing Activities in USD of Arbutus Biopharma Corp from 2011 to Q1 2025

Taxonomy & unit
us-gaap: USD and CAD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
Arbutus Biopharma Corp quarterly/annual Net Cash Provided by (Used in) Financing Activities history and change rate from 2011 to Q1 2025.
  • Arbutus Biopharma Corp Net Cash Provided by (Used in) Financing Activities for the quarter ending 31 Mar 2025 was $2.78M, a 88.6% decline year-over-year.
  • Arbutus Biopharma Corp annual Net Cash Provided by (Used in) Financing Activities for 2024 was $52M, a 69.7% increase from 2023.
  • Arbutus Biopharma Corp annual Net Cash Provided by (Used in) Financing Activities for 2023 was $30.6M, a 3.67% decline from 2022.
  • Arbutus Biopharma Corp annual Net Cash Provided by (Used in) Financing Activities for 2022 was $31.8M, a 76.8% decline from 2021.
Net Cash Provided by (Used in) Financing Activities, Trailing 12 Months (USD)
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Change (%)
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Change (%)

Arbutus Biopharma Corp Quarterly Net Cash Provided by (Used in) Financing Activities (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2025 $2.78M -$21.6M -88.6% 01 Jan 2025 31 Mar 2025 10-Q 14 May 2025
Q1 2024 $24.4M +$4.01M +19.7% 01 Jan 2024 31 Mar 2024 10-Q 14 May 2025
Q1 2023 $20.4M +$8.93M +77.8% 01 Jan 2023 31 Mar 2023 10-Q 02 May 2024
Q1 2022 $11.5M -$15.4M -57.3% 01 Jan 2022 31 Mar 2022 10-Q 04 May 2023
Q1 2021 $26.9M +$14.4M +115% 01 Jan 2021 31 Mar 2021 10-Q 05 May 2022
Q1 2020 $47.4M $12.5M +$9.95M +392% 01 Jan 2020 31 Mar 2020 10-Q 05 May 2021
Q4 2019 $37.5M $13.9M +$13.8M +12646% 01 Oct 2019 31 Dec 2019 10-K 04 Mar 2021
Q3 2019 $23.7M $18.5M +$18.1M +4164% 01 Jul 2019 30 Sep 2019 10-Q 06 Nov 2019
Q2 2019 $5.56M $2.48M +$1.74M +237% 01 Apr 2019 30 Jun 2019 10-Q 05 Aug 2019
Q1 2019 $3.82M $2.54M -$51.8M -95.3% 01 Jan 2019 31 Mar 2019 10-Q 11 May 2020
Q4 2018 $55.6M $109K -$48.8M -99.8% 01 Oct 2018 31 Dec 2018 10-K 05 Mar 2020
Q3 2018 $104M $435K +$374K +613% 01 Jul 2018 30 Sep 2018 10-Q 06 Nov 2019
Q2 2018 $104M $735K +$731K 01 Apr 2018 30 Jun 2018 10-Q 05 Aug 2019
Q1 2018 $103M $54.4M +$54M +15258% 01 Jan 2018 31 Mar 2018 10-Q 06 May 2019
Q4 2017 $49.3M $48.9M +$36.9M +307% 01 Oct 2017 31 Dec 2017 10-K 07 Mar 2019
Q3 2017 $12.4M $61K -$15K -19.7% 01 Jul 2017 30 Sep 2017 10-Q 07 Nov 2018
Q2 2017 $12.4M $4K* -$442K 01 Apr 2017 30 Jun 2017 10-Q 03 Aug 2018
Q1 2017 $12.9M $354K +$239K +208% 01 Jan 2017 31 Mar 2017 10-Q 04 May 2018
Q4 2016 $12.6M $12M +$12M 01 Oct 2016 31 Dec 2016 10-K 16 Mar 2018
Q3 2016 $611K $76K -$40K -34.5% 01 Jul 2016 30 Sep 2016 10-Q 02 Nov 2017
Q2 2016 $651K $446K -$514K -53.5% 01 Apr 2016 30 Jun 2016 10-Q 03 Aug 2017
Q1 2016 $1.17M $115K -$143M -99.9% 01 Jan 2016 31 Mar 2016 10-Q 04 May 2017
Q4 2015 $144M -$26K -$495K -106% 01 Oct 2015 31 Dec 2015 10-K 16 Mar 2018
Q3 2015 $144M $116K -$568K -83% 01 Jul 2015 30 Sep 2015 10-Q 03 Nov 2016
Q2 2015 $145M $960K +$726K +310% 01 Apr 2015 30 Jun 2015 10-Q 04 Aug 2016
Q1 2015 $144M $143M +$83.5M +141% 01 Jan 2015 31 Mar 2015 10-Q 04 May 2016
Q4 2014 $60.7M $469K 01 Oct 2014 31 Dec 2014 10-K 22 Mar 2017
Q3 2014 $684K 01 Jul 2014 30 Sep 2014 10-Q 05 Nov 2015
Q2 2014 $234K +$158K +208% 01 Apr 2014 30 Jun 2014 10-Q 07 Aug 2015
Q1 2014 $59.3M +$59.2M +42863% 01 Jan 2014 31 Mar 2014 10-Q 06 May 2015
Q2 2013 $76K 01 Apr 2013 30 Jun 2013 10-Q 07 Nov 2014
Q1 2013 $138K 01 Jan 2013 31 Mar 2013 10-Q 14 May 2014

Arbutus Biopharma Corp Annual Net Cash Provided by (Used in) Financing Activities (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $52M +$21.3M +69.7% 01 Jan 2024 31 Dec 2024 10-K 27 Mar 2025
2023 $30.6M -$1.17M -3.67% 01 Jan 2023 31 Dec 2023 10-K 27 Mar 2025
2022 $31.8M -$105M -76.8% 01 Jan 2022 31 Dec 2022 10-K 05 Mar 2024
2021 $137M +$50.5M +58.2% 01 Jan 2021 31 Dec 2021 10-K 02 Mar 2023
2020 $86.7M +$49.3M +132% 01 Jan 2020 31 Dec 2020 10-K 03 Mar 2022
2019 $37.5M -$18.2M -32.7% 01 Jan 2019 31 Dec 2019 10-K 04 Mar 2021
2018 $55.6M +$6.32M +12.8% 01 Jan 2018 31 Dec 2018 10-K 05 Mar 2020
2017 $49.3M +$36.7M +290% 01 Jan 2017 31 Dec 2017 10-K 07 Mar 2019
2016 $12.6M -$131M -91.2% 01 Jan 2016 31 Dec 2016 10-K 16 Mar 2018
2015 $144M +$83.2M +137% 01 Jan 2015 31 Dec 2015 10-K 16 Mar 2018
2014 $60.7M +$28M +85.5% 01 Jan 2014 31 Dec 2014 10-K 22 Mar 2017
2013 $32.7M +$28.2M +620% 01 Jan 2013 31 Dec 2013 10-K 09 Mar 2016
2012 $4.55M -$62.6K -1.36% 01 Jan 2012 31 Dec 2012 10-K 13 Mar 2015
2011 $4.61M 01 Jan 2011 31 Dec 2011 10-K 28 Mar 2014
* An asterisk sign (*) next to the value indicates that the value is likely invalid.